tldrdailynews.com logo

Regeneron Reevaluates Bispecific Antibody Strategy Following Fatalities

1 min read
Source: Endpoints News
Regeneron Reevaluates Bispecific Antibody Strategy Following Fatalities
Photo: Endpoints News
TL;DR

Regeneron is reassessing its PSMA/CD28 bispecific antibody development in prostate cancer after two patient deaths occurred during a combination trial with Libtayo. The company has halted patient enrollment in the trial due to the emerging safety profile, including the deaths.

Topics:businesshealthcare#bispecific-antibody#healthcare#immunotherapy#patient-deaths#prostate-cancer#regeneron
Share this article
  1. Regeneron reviews plans for bispecific antibody after two patient deaths  Endpoints News
  2. Regeneron rethinks CD28 bispecific R&D plan after 2 patients die  FierceBiotech
  3. View Full Coverage on Google News

Want the full story? Read the original reporting

Read on Endpoints News